Cor Vasa 2016, 58(4):e431-e438 | DOI: 10.1016/j.crvasa.2015.08.003
Cardiac cachexia - Up-to-date 2015
- Interní klinika, Krajská nemocnice T. Bati, a. s., Zlín, Česká republika
Cachexia is defined as unintended loss of 5% of the original body weight of a patient with edema within 3-12 months in combination with typical symptoms of a chronic disease. Prevalence of cardiac cachexia (CC) in chronic heart failure (CHF) is 5-15%, with an annual mortality rate of 20-30%. The condition involves loss of lean body mass (skeletal muscle), body fat, and, to a lesser extent, also bone tissue. In pathophysiological terms, cachexia is associated with complex alterations in neurohormonal and immunological status, catabolism prevailing over anabolism, and activation of pro-inflammatory cytokines, with the key role played by TNF-α. The pro-inflammatory response is believed to be induced by reduced blood supply to the intestine and intestinal wall edema in the presence of congestion facilitating entry of bacteria and endotoxins into the circulation. Other processes include reduced perfusion of the skeletal muscle, its atrophy, and abnormal myocyte metabolism characterized by depletion of energy-rich substances (loss of ATP, creatine, and glycogen), excess of water and lactate, as well as impaired oxidative metabolism. Research at the level of the "atrophising" muscle cell has focused on the ubiquitin-proteasome system, growth differentiation factor-15, myostatin, and other muscle cell regulatory proteins. Novel biomarkers of CC, anabolism/catabolism, and skeletal muscle status include ghrelin, adiponectin, C-terminal agrin fragment, growth differentiation factor-15, N-terminal propeptide of type III procollagen, myostatin, and D3-creatine estimated using the dilution method. Promising results in the treatment of cachexia have been reported with ghrelin receptor agonists (anamorelin), selective androgen receptor modulators (enobosarm), and some betablockers (espindolol); research into myostatin antagonists is under way. Aerobic exercise has been shown to have a beneficial effect. Though recommended, no hard data are currently available to document the value of nutritional support.
Keywords: Biomarkers; Cardiac cachexia; Chronic heart failure; Nutritional support
Received: June 2, 2015; Revised: August 9, 2015; Accepted: August 11, 2015; Published: August 1, 2016 Show citation
References
- A.M. Katz, P.B. Katz, Disease of the heart in works of Hippocrates, British Heart Journal 24 (1962) 257-262.
Go to original source...
- W.J. Evans, J.E. Morley, J. Argiles, et al., Cachexia: a new definition, Clinical Nutrition 7 (2008) 793-799.
Go to original source...
Go to PubMed...
- S.D. Anker, M. John, P.U. Pedersen, et al., ESPEN guidelines on enteral nutrition: cardiology and pulmonology, Clinical Nutrition 25 (2006) 311-318.
Go to original source...
Go to PubMed...
- A. Fanzani, V.M. Conraads, F. Penna, W. Martinet, Molecular and cellular mechanisms of skeletal muscle atrophy: an update, Journal of Cachexia, Sarcopenia and Muscle 3 (2012) 163-179.
Go to original source...
Go to PubMed...
- S.D. Anker, S. von Haehling, Efforts begin to sprout: publications in JCSM on cachexia, sarcopenia and muscle wasting receive attention, Journal of Cachexia, Sarcopenia and Muscle 5 (2014) 171-176.
Go to original source...
Go to PubMed...
- S.T. Arthur, J.M. Noone, B.A. Van Doren, et al., One-year prevalence, comorbidities and cost of cachexia-related inpatient admissions in the USA, Drugs in Context 3 (2014) 212265.
Go to original source...
Go to PubMed...
- J. Farkas, S. von Haehling, K. Kalantar-Zadeh, et al., Cachexia as a major public health problem: frequent, costly, and deadly, Journal of Cachexia, Sarcopenia and Muscle 4 (2013) 173-178.
Go to original source...
Go to PubMed...
- S.D. Anker, A.J.S. Coats, Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation, Chest 115 (1999) 836-847.
Go to original source...
Go to PubMed...
- S. von Haehling, S.D. Anker, Prevalence, incidence and clinical impact of cachexia: facts and numbers - update 2014, Journal of Cachexia, Sarcopenia and Muscle 5 (2014) 261-263.
Go to original source...
Go to PubMed...
- S.D. Anker, A. Negassa, A.J. Coats, et al., Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting enzyme inhibitors: an observational study, Lancet 361 (2003) 1077-1083.
Go to original source...
Go to PubMed...
- S.D. Anker, P. Ponikowski, S. Varney, et al., Wasting as independent risk factor of survival in chronic heart failure, Lancet 349 (1997) 1050-1053.
Go to original source...
Go to PubMed...
- S.D. Anker, R. Sharma, The syndrome of cardiac cachexia, International Journal of Cardiology 85 (2002) 51-66.
Go to original source...
- L.M. Freeman, R. Roubenoff, The nutrition implications of cardiac cachexia, Nutrition Reviews 52 (1994) 340-347.
Go to original source...
Go to PubMed...
- S. von Haehling, M. Lainscak, J. Springer, S.D. Anker, Cardiac cachexia: a systematic overview, Pharmacology & Therapeutics 121 (2009) 227-252.
Go to original source...
Go to PubMed...
- V. Melenovsky, M. Kotrc, B.A. Borlaug, et al., Relationships between right ventricular function, body composition and prognosis in heart failure, Journal of the American College of Cardiology 62 (2013) 1660-1670.
Go to original source...
Go to PubMed...
- M.A. Cicoira, W. Doehner, W.A. Jankowska, et al., Body composition and prognosis in 511 chronic heart failure patients: results from three European centers, European Journal of Heart Failure Supplements 3 (Suppl.) (2004) 69.
Go to original source...
- S.B. Heymsfield, K. Casper, Congestive heart failure: clinical management by use of continuous nasoenteric feeding, American Journal of Clinical Nutrition 50 (1989) 539-544.
Go to original source...
Go to PubMed...
- I. Mustafa, X. Leverve, Metabolic and nutritional disorders in cardiac cachexia, Nutrition 17 (2001) 756-760.
Go to original source...
Go to PubMed...
- C. Berry, A.L. Clark, Catabolism in chronic heart failure, European Heart Journal 21 (2000) 521-532.
Go to original source...
- S. von Haehling, W. Doehner, S.D. Anker, Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure, Cardiovascular Research 73 (2007) 298-309.
Go to original source...
Go to PubMed...
- K. Kalantar-Zadeh, S.D. Anker, T.B. Horwich, G.C. Fonarow, Nutritional and anti-inflammatory interventions in chronic heart failure, American Journal of Cardiology 101 (11A) (2008) 89E-103E.
Go to original source...
Go to PubMed...
- E.T. Poehlmann, J. Scheffers, S.S. Gottlieb, et al., Increased resting metabolic rate in patients with congestive heart failure, Annals of Internal Medicine 121 (1994) 860-862.
Go to original source...
- S.B. Heymsfield, J. Smith, S. Redd, H.B. Whitworth, Nutritional support in cardiac failure, Surgical Clinics of North America 61 (1981) 635-652.
Go to original source...
Go to PubMed...
- M.J. Toth, S.S. Gottlieb, M.I. Goran, et al., Daily energy expenditure in freeliving heart failure patients, American Journal of Physiology 272 (1997) 469-475.
Go to original source...
- R. Aquilani, C. Opasich, M. Verri, et al., Is nutritional intake adequate in chronic heart failure patients?, Journal of the American College of Cardiology 42 (2003) 1218-1223.
Go to original source...
Go to PubMed...
- E. Pasini, C. Opasich, O. Pastoris, R. Aquilani, Inadequate nutritional intake for daily life activity of clinically stable patients with chronic heart failure, American Journal of Cardiology 93 (8A) (2004) 41A-43A.
Go to original source...
Go to PubMed...
- K.K. Witte, A.L. Clark, J.G. Cleland, Chronic heart failure and micronutrients, Journal of the American College of Cardiology 37 (2001) 1765-1774.
Go to original source...
Go to PubMed...
- S.R. Krim, P. Campbell, C.J. Lavie, H. Ventura, Micronutrients in chronic heart failure, Current Heart Failure Reports 10 (2013) 46-53.
Go to original source...
Go to PubMed...
- D.M. Mancini, G. Walter, N. Reichek, et al., Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in heart failure, Circulation 85 (1992) 1364-1373.
Go to original source...
Go to PubMed...
- A.A. Ajayi, A.Q. Adiqun, E.O. Ojofeitimi, et al., Anthropometric evaluation of cachexia in chronic congestive heart failure: the role of tricuspid regurgitation, International Journal of Cardiology 71 (1999) 79-84.
Go to original source...
Go to PubMed...
- S.D. Anker, P.P. Ponikowski, A.L. Clark, et al., Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure, European Heart Journal 20 (1999) 683-693.
Go to original source...
Go to PubMed...
- S.D. Anker, M. Volterrani, C.-D. Pflaum, et al., Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone, Journal of the American College of Cardiology 38 (2001) 443-452.
Go to original source...
Go to PubMed...
- M. Rauchhaus, W. Doehner, D.P. Francis, et al., Plasma cytokine parameters and mortality in patients with chronic heart failure, Circulation 102 (2000) 3060-3067.
Go to original source...
- J. Springer, G. Filippatos, Y.J. Akashi, S.D. Anker, Prognosis and therapy approaches of cardiac cachexia, Current Opinion in Cardiology 21 (2006) 229-233.
Go to original source...
Go to PubMed...
- T. Martins, R. Vitorino, D. Moreira-Gonçalves, et al., Recent insights on the molecular mechanisms and therapeutic approaches for cardiac cachexia, Clinical Biochemistry 47 (2014) 8-15.
Go to original source...
Go to PubMed...
- A. Sandek, A. Swidsinski, W. Schroedl, et al., Intestinal blood flow in patients with chronic heart failure: a link with bacterial growth, gastrointestinal symptoms, and cachexia, Journal of the American College of Cardiology 64 (2014) 1092-1102.
Go to original source...
Go to PubMed...
- D. King, M.L. Smith, M. Lye, Gastro-intestinal protein loss in elderly patients with cardiac cachexia, Age and Ageing 25 (1996) 221-223.
Go to original source...
Go to PubMed...
- D. King, M.L. Smith, T.J. Chapman, et al., Fat malabsorption in elderly patients with cardiac cachexia, Age and Ageing 25 (1996) 144-149.
Go to original source...
Go to PubMed...
- A. Krack, R. Sharma, H.R. Figulla, S.D. Anker, The importance of the gastrointestinal system in the pathogenesis of heart failure, European Heart Journal 26 (2005) 2368-2374.
Go to original source...
Go to PubMed...
- S.D. Anker, T.P. Chua, J.W. Swan, et al., Hormonal changes and catabolic/anabolic imbalance in chronic heart failure: the importance for cardiac cachexia, Circulation 96 (1997) 526-534.
Go to original source...
- M. Rauchhaus, A.L. Clark, W. Doehner, et al., The relationship between cholesterol and survival in patients with chronic heart failure, Journal of the American College of Cardiology 42 (2003) 1933-1940.
Go to original source...
Go to PubMed...
- L.C. Hudgins, T.S. Parker, D.M. Levine, et al., A single intravenous dose of endotoxin rapidly alters serum lipoproteins and lipid transfer proteins in normal volunteers, Journal of Lipid Research 44 (2003) 1489-1498.
Go to original source...
Go to PubMed...
- M. Rauchhaus, A.J. Coats, S.D. Anker, The endotoxin-lipoprotein hypothesis, Lancet 356 (2000) 930-933.
Go to original source...
Go to PubMed...
- M.J. Sullivan, J.D. Knight, M.B. Higginbotham, F.R. Cobb, Relation between central and peripheral hemodynamics during exercise in patients with chronic heart failure, Circulation 80 (1989) 769-781.
Go to original source...
- M.J. Sullivan, H.J. Green, F.R. Cobb, Skeletal muscle biochemistry and histology in ambulatory patients with long-term heart failure, Circulation 81 (1990) 518-527.
Go to original source...
- M. Schaufelberger, B.O. Eriksson, G. Grimby, et al., Skeletal muscle alterations in patients with chronic heart failure, European Heart Journal 18 (1997) 971-980.
Go to original source...
- N. Ebner, L. Steinbeck, W. Doehner, et al., Highlights from the 7th cachexia conference: Muscle wasting pathophysiological detection and novel treatment strategies, Journal of Cachexia, Sarcopenia and Muscle 5 (2014) 27-34.
Go to original source...
Go to PubMed...
- M. Broqvist, H. Arnqvist, U. Dahlström, et al., Nutritional assessment and muscle energy metabolism in severe chronic congestive heart failure effects of long-term dietary supplementation, European Heart Journal 15 (1994) 1641-1650.
Go to original source...
- G. Loncar, D. Omersa, N. Cvetinovic, et al., Emerging biomarkers in heart failure and cardiac cachexia, International Journal of Molecular Sciences 15 (2014) 23878-23896.
Go to original source...
Go to PubMed...
- G. Baldanzi, N. Filigheddu, S. Cutrupi, et al., Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT, Journal of Cell Biology 159 (2002) 1029-1037.
Go to original source...
Go to PubMed...
- G. Filippatos, S.D. Anker, D. Kremastinos, Pathophysiology of peripheral muscle wasting in cardiac cachexia, Current Opinion in Clinical Nutrition and Metabolic Care 8 (2005) 249-254.
Go to original source...
Go to PubMed...
- P. Attanasio, S.D. Anker, W. Doehner, S. von Haehling, Hormonal consequences and prognosis of chronic heart failure, Current Opinion in Endocrinology, Diabetes and Obesity 18 (2011) 224-230.
Go to original source...
Go to PubMed...
- T. Szabó, N. Scherbakov, A. Sandek, et al., Plasma adiponectin in heart failure with and without cachexia: catabolic signal linking catabolism, symptomatic status, and prognosis, Nutrition, Metabolism, and Cardiovascular Diseases 24 (2014) 50-56.
Go to original source...
Go to PubMed...
- M.B. McEntegart, B. Awede, M.C. Petrie, et al., Increase in serum adiponectin concentration in patients with heart failure and cachexia: Relationship with leptin, other cytokines, and B-type natriuretic peptide, European Heart Journal 28 (2007) 829-835.
Go to original source...
Go to PubMed...
- F. Strasser, Clinical application of ghrelin, Current Pharmaceutical Design 18 (2012) 4800-4812.
Go to original source...
- F. Leyva, S.D. Anker, K. Egerer, et al., Hyperleptinaemia in chronic heart failure. Relationships with insulin, European Heart Journal 19 (1998) 1547-1551.
Go to original source...
- M.S. Fragala, A.R. Jajtner, K.S. Beyer, et al., Biomarkers of muscle quality: N-terminal propeptide of type III procollagen and C-terminal agrin fragment responses to resistance exercise training in older adults, Journal of Cachexia, Sarcopenia and Muscle 5 (2014) 139-148.
Go to original source...
Go to PubMed...
- T. Martins, R. Vitorino, F. Amado, et al., Biomarkers for cardiac cachexia: reality or utopia, Clinica Chimica Acta 436 (2014) 323-328.
Go to original source...
Go to PubMed...
- S. Bhasin, E.J. He, M. Kawakubo, et al., N-terminal propeptide of type III procollagen as a biomarker of anabolic response to recombinant human GH and testosterone, Journal of Clinical Endocrinology and Metabolism 94 (2009) 4224-4233.
Go to original source...
Go to PubMed...
- A. Nedergaard, S. Sun, M.A. Karsdal, et al., Type VI collagen turnover-related peptides-novel serological biomarkers of muscle mass and anabolic response to loading in young men, Journal of Cachexia, Sarcopenia and Muscle 4 (2013) 267-275.
Go to original source...
Go to PubMed...
- S.A. Stimpson, M.S. Leonard, L.G. Clifton, et al., Longitudinal changes in total body creatine pool size and skeletal muscle mass using the d-creatine dilution method, Journal of Cachexia, Sarcopenia and Muscle 4 (2013) 217-223.
Go to original source...
Go to PubMed...
- D.L. Mann, J.J. McMurray, M. Packer, et al., Targeted anticytokine therapy in patients with chronic heart failure, Circulation 109 (2004) 1594-1602.
Go to original source...
Go to PubMed...
- S.D. Anker, A.J.S. Coats, How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH, International Journal of Cardiology 86 (2002) 123-130.
Go to original source...
- E.S. Chung, M. Packer, K.H. Lo, et al., Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α in patients with moderate-to-severe heart failure, Circulation 107 (2003) 3133-3140.
Go to original source...
Go to PubMed...
- E. Bocchi, L. Moura, G. Guimaraes, et al., Beneficial effects of high doses of growth hormone in the introduction and optimization of medical treatment in decompensated congestive heart failure, International Journal of Cardiology 110 (2005) 313-317.
Go to original source...
Go to PubMed...
- S. Fazio, D. Sabatini, B. Capaldo, et al., A preliminary study of growth hormone in the treatment of dilated cardiomyopathy, New England Journal of Medicine 334 (1996) 809-814.
Go to original source...
Go to PubMed...
- K.J. Osterziel, O. Strohm, J. Schuler, et al., Randomised, double-blind, placebo controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy, Lancet 351 (1998) 1233-1237.
Go to original source...
Go to PubMed...
- J. Temel, S. Bondarde, M. Jain, et al., Efficacy and safety results from a phase II study of anamorelin HCl, a ghrelin receptor agonist, in NSCLC patients, Journal of Cachexia, Sarcopenia and Muscle 4 (2013) 295-343.
Go to original source...
Go to PubMed...
- C.J. Malkin, P.J. Pugh, J.N. West, et al., Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial, European Heart Journal 27 (2006) 57-64.
Go to original source...
Go to PubMed...
- J.T. Dalton, K.G. Barnette, C.E. Bohl, et al., The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial, Journal of Cachexia, Sarcopenia and Muscle 2 (2011) 153-161.
Go to original source...
Go to PubMed...
- R. Bauerlein, J. Pangilinan, R. Salzler, et al., Efficacy of REGN1033, a fully human anti-myostatin antagonist antibody, in rodent muscle function, Journal of Cachexia, Sarcopenia and Muscle 4 (2013) 295-343.
Go to original source...
Go to PubMed...
- K.R. Wagner, J.L. Fleckenstein, A.A. Amato, et al., A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy, Annals of Neurology 63 (2008) 561-571.
Go to original source...
Go to PubMed...
- R. Piccirillo, A.L. Goldberg, The p97/VCP ATPase is critical in muscle atrophy and for the accelerated degradation of most muscle proteins, Journal of Cachexia, Sarcopenia and Muscle 4 (2013) 295-343.
Go to original source...
Go to PubMed...
- D.N. Herndon, D.W. Hart, S.E. Wolf, et al., Reversal of catabolism by betablockade after severe burns, New England Journal of Medicine 345 (2001) 1223-1229.
Go to original source...
Go to PubMed...
- Beta-Blocker Heart Attack Trial Research Group, A randomised trial of propranolol in patients with acute myocardial infarction. Mortality results, Journal of the American Medical Association 247 (1982) 1707-1714.
Go to original source...
- K. Hryniewicz, A.S. Androne, A. Hudaihed, S. Katz, Partial reversal of cachexia by beta-adrenergic receptor blocker therapy in patients with chronic heart failure, Journal of Cardiac Failure 9 (2003) 464-468.
Go to original source...
Go to PubMed...
- S. Palus, K. Hartmann, T. Braun, et al., Beta-blocker for the treatment of cancer cachexia: are they all equal?, Journal of Cachexia, Sarcopenia and Muscle 5 (2014), abstract 4-19.
- V. Musolino, A. Tschirner, M. Pötsch, et al., MT-102 a new anabolic catabolic transforming agent improves heart function in a rat model of cancer cachexia, Journal of Cachexia, Sarcopenia and Muscle 5 (2014) abstract 3-36.
- A.J. Stewart Coats, V. Srinivasan, J. Surendran, et al., The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design, Journal of Cachexia, Sarcopenia and Muscle 2 (2011) 201-207.
Go to original source...
Go to PubMed...
- S.D. Anker, J.W. Swan, M. Volterrani, et al., The influence of muscle mass, strength, fatigability and blood flow on exercise capacity in cachectic and non-cachectic patients with chronic heart failure, European Heart Journal 18 (1997) 259-269.
Go to original source...
- Y.-H. Song, Y. Li, J. Du, et al., Muscle-specific expression of IGF-1 blocks angiotensin-induced skeletal muscle wasting, Journal of Clinical Investigation 115 (2005) 451-458.
Go to original source...
Go to PubMed...
- R. Gennari, J.W. Alexander, S.T. Boyce, et al., Effects of the angiotensin converting enzyme inhibitor enalapril on bacterial translocation after thermal injury and bacterial challenge, Shock 6 (1996) 95-100.
Go to original source...
Go to PubMed...
- I. Bourdel-Marchasson, C. Blanc-Bisson, A. Doussau, et al., Nutritional advice in older patients at risk of malnutrition during treatment for chemotherapy: a two-year randomized controlled trial, PLOS ONE 9 (2014) e108687.
Go to original source...
Go to PubMed...
- P. Rozentryt, S. von Haehling, M. Lainscak, et al., The effects of a high-caloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double-blind pilot study, Journal of Cachexia, Sarcopenia and Muscle 1 (2010) 35-42.
Go to original source...
Go to PubMed...
- G.P. Arutiunov, O.I. Kostiukevich, N.V. Rylova, et al., Effect of enteral feeding on exercise tolerance and clinical picture in patients with NYHA class III-IV chronic heart failure, Kardiologiia 43 (2003) 52-55.
- M. Otaki, Surgical treatment of patients with cardiac cachexia. An analysis of factors affecting operative mortality, Chest 105 (1994) 1347-1351.
Go to original source...
Go to PubMed...
- S. Mogami, H. Tsubouchi, S. Yanagi, et al., Rikkunshito, a Japasese Kampo medicine, ameliorates anorexia and muscle wasting via ghrelin secretion in mice with bleomycin-induced pulmonary fibrosis, Journal of Cachexia, Sarcopenia and Muscle 5 (2014) abstract 4-15.
- A.J. Coats, S. Adamopoulos, T.E. Meyer, et al., Effects of physical training in chronic heart failure, Lancet 335 (1990) 63-66.
Go to original source...
- P.C. Schulze, S. Gielen, G. Schuler, R. Hambrecht, Chronic heart failure and skeletal muscle catabolism: effect of exercise training, International Journal of Cardiology 85 (2002) 141-149.
Go to original source...
- C.M. O'Connor, D.J. Whellan, K.L. Lee, et al., Efficacy and safety of exercise training in patients with chronic heart failure. HF-ACTION randomized controlled trial, Journal of the American Medical Association 301 (2009) 1439-1450.
Go to original source...
Go to PubMed...
- R.W. Souza, W.P. Piedade, L.C. Soares, et al., Aerobic exercise training prevents heart failure-induced skeletal muscle atrophy by anti-catabolic, but not anabolic actions, PLOS ONE 9 (2014) e110020.
Go to original source...
Go to PubMed...
- M. Quittan, G.F. Wiesinger, B. Sturm, et al., Improvement of thigh muscles by neuromuscular electrical stimulation in patients with refractory heart failure: a single-blind, randomized, controlled trial, American Journal of Physical Medicine & Rehabilitation 80 (2001) 206-214.
Go to original source...
Go to PubMed...
- M. Maddocks, W. Gao, I.J. Higginson, A. Wilcock, Neuromuscular electrical stimulation for muscle weakness in adults with advanced disease, Cochrane Database of Systematic Reviews 1 (January) (2013), CD009419.
Go to original source...
Go to PubMed...
- C.J. de Araújo, F.S. Gonçalves, H.S. Bittencourt, et al., Effects of neuromuscular electrostimulation in patients with heart failure admitted to ward, Journal of Cardiothoracic Surgery 7 (2012) 124.
Go to original source...
Go to PubMed...